SCHEMBL749157

SCHEMBL749157

CC(=O)n1cnc(C[C@H](NC(=O)CCN)C(=O)O)c1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CPB2 Q96IY4 14/20 0.49
CPB1 P15086 7/20 0.47
ITGB3 P05106 3/20 0.40
ITGA2B P08514 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17044394 1.00 CPB2 (0.49) CPB2CPB1ITGB3ITGA2B
SCHEMBL22392864 1.00 CPB2 (0.49) CPB2CPB1ITGB3ITGA2B
SCHEMBL636655 1.00 CPB2 (0.49) CPB2CPB1ITGB3ITGA2B
SCHEMBL8896989 0.99 CPB2 (0.48) CPB2CPB1ITGB3ITGA2B
SCHEMBL9110288 0.99 CPB2 (0.48) CPB2CPB1ITGB3ITGA2B
SCHEMBL5663758 0.88 CPB2 (0.50) CPB2CPB1ITGB3ITGA2B
SCHEMBL5964769 0.88 CPB2 (0.48) CPB2CPB1ITGB3ITGA2B
SCHEMBL4393104 0.88 HDAC6 (0.47) CPB2CPB1
SCHEMBL5964147 0.88 CPB2 (0.50) CPB2CPB1ITGB3ITGA2B
SCHEMBL11225379 0.87 CPB2 (0.49) CPB2CPB1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119970545-A Composite carnosine composition and preparation method thereof 苏州富士莱医药股份有限公司 2025-05-13 CN claimed
CN-119735552-A Synthesis method of N-acetyl-L-carnosine 甘肃瑞德林生物有限公司 2025-04-01 CN claimed
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes CROSS III WILLIAM H (US) 2023-10-05 US claimed
US-11684623-B2 Soluble melatonin tripartate adduct for the prevention and treatment of rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders WORPHMED SRL (IT) 2023-06-27 US claimed
US-11612632-B2 Compositions and methods for treatment of prediabetes CROSS III WILLIAM H (US) 2023-03-28 US claimed
CN-114295755-A Marker for early diagnosis of gestational diabetes and application thereof 华中科技大学 2022-04-08 CN claimed
CN-111480740-A Preparation and application of high-nutrition nonpregnant sow feed 叶平凡 2020-08-04 CN claimed
CN-111466491-A Preparation of feed additive for nonpregnant sows 叶平凡 2020-07-31 CN claimed
US-10406383-B2 Apparatus for treatment of dermatological conditions CAREWEAR CORP. (US) 2019-09-10 US claimed
US-20180303896-A1 Compositions and Methods for Treatment of Prediabetes CROSS III WILLIAM H (US) 2018-10-25 US claimed
EP-2431075-B1 Apparatus for treatment of dermatological conditions SONOVIA HOLDINGS LLC (US) 2017-04-05 EP claimed
US-20140086855-A1 COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME INNOVATIVE VISION PRODUCTS, INC. (US) 2014-03-27 US claimed
EP-2431075-A1 Apparatus for treatment of dermatological conditions Sonovia Limited (GB) 2012-03-21 EP claimed
CN-101585813-B Prepartion method of N-acetyl-L-carnosine CHANGSHU FUSHILAI MEDICINE & CHEMICAL CO LTD 2011-04-13 CN claimed
US-20100330170-A1 Flavored Vegetarian Cellulose Capsule and Methods for Producing said Capsule CAPSULINE, INC. (US) 2010-12-30 US claimed
CN-101585813-A Prepartion method of N-acetyl-L-carnosine CHANGSHU FUSLAI PHARMACEUTICAL (CN) 2009-11-25 CN claimed
US-20060222699-A1 FLAVORED VEGETARIAN CELLULOSE CAPSULE AND METHODS FOR PRODUCING SAID CAPSULE. CAPSULE, INC. 2006-10-05 US claimed
US-20060116328-A1 Combined use of carnosinase inhibitor with l-carnosines and composition INNOVATIVE VISION PRODUCTS, INC. 2006-06-01 US claimed
EP-1586332-A1 COMBINED USE OF CARNOSINASE INHIBITOR WITH L-CARNOSINES AND COMPOSITION Innovative Vision Products, Inc. (US) 2005-10-19 EP claimed
US-4387232-A Process for preparing N-acylcarnosine AJINOMOTO COMPANY INCORPORATED (JP) 1983-06-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11684623-B2 Soluble melatonin tripartate adduct for the prevention and treatment of rare and severe eye sight-threatening conditions and neuro-ophthalmic disorders HIF1A, HIF1AN, MTNR1A CPB2 4315/4885CPB1 4244/4885ITGB3 2469/4885
US-20060116328-A1 Combined use of carnosinase inhibitor with l-carnosines and composition LCT, ADH1C, PON1 CPB2 550/4885CPB1 223/4885ITGB3 4835/4885
US-11612632-B2 Compositions and methods for treatment of prediabetes GPX1, GPX4, GLS2 CPB2 1213/4885CPB1 1596/4885ITGB3 1151/4885
US-20140086855-A1 COMBINED USE OF A CARNOSINASE INHIBITOR WITH L-CARNOSINE OR ITS RELATED SUBSTANCE AND A COMPOSITION CONTAINING THE SAME LCT, CPA1, ADH1C CPB2 379/4885CPB1 146/4885ITGB3 4842/4885
US-20230310461-A1 Compositions and Methods for Treatment of Prediabetes GPX1, GPX4, NFE2L2 CPB2 2518/4885CPB1 2815/4885ITGB3 532/4885
US-20180303896-A1 Compositions and Methods for Treatment of Prediabetes GPX1, GPX4, GLS2 CPB2 1213/4885CPB1 1596/4885ITGB3 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.